Payment overview · 2025
General Payments
$15,685.63
161 reported records · 10 companies
Healthcare provider profile · identity verified
Benjamin Jenny, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · MESA, AZ · NPI 1629413828
Verified facts
What the public records show
CMS Open Payments records show Benjamin Jenny, M.D. received $15,685.63 in general payments during 2025 across 161 reported records.
Impulse Dynamics (USA) Inc. accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $5,649.54 | 36.0% | 16 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $2,509.36 | 16.0% | 30 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $2,483.55 | 15.8% | 37 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,158.04 | 13.8% | 19 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,350.55 | 8.6% | 24 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $469.52 | 3.0% | 14 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $371.61 | 2.4% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$350.77 | 2.2% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $189.20 | 1.2% | 8 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $153.49 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,154.00 | 7 |
| Food and Beverage | $6,994.43 | 148 |
| Travel and Lodging | $1,537.20 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $1,798.93 | 21 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $1,378.65 | 8 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $1,352.62 | 13 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $1,200.52 | 11 | 2025 |
Source payment records
|
|||||
| QDOT MICRO Normalized: qdot micro |
Device | Biosense Webster, Inc. | $837.46 | 12 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $625.00 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $544.30 | 5 | 2025 |
Source payment records
|
|||||
| TEG5000 HEMOSTASIS ANALYZER Normalized: teg5000 hemostasis analyzer |
Device | CARDIVA MEDICAL, INC. | $500.00 | 1 | 2025 |
Source payment records
|
|||||
| TEG6S HEMOSTASIS SYSTEM Normalized: teg6s hemostasis system |
Device | CARDIVA MEDICAL, INC. | $500.00 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $444.81 | 13 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $371.61 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $359.26 | 16 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $191.66 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $189.20 | 8 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $182.80 | 3 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $159.69 | 13 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $153.49 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Steerable Access Solution Normalized: versacross steerable access solution |
Device | Boston Scientific Corporation | $149.39 | 1 | 2025 |
Source payment records
|
|||||
| VIEWMATE Normalized: viewmate |
Device | Abbott Laboratories | $142.63 | 1 | 2025 |
Source payment records
|
|||||
| REVEAL LINQ Normalized: reveal linq |
Device | Medtronic, Inc. | $141.22 | 1 | 2025 |
Source payment records
|
|||||
| OCTARAY MAPPING CATHETER Normalized: octaray mapping catheter |
Device | Biosense Webster, Inc. | $136.48 | 2 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $133.30 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $78.04 | 3 | 2025 |
Source payment records
|
|||||
| VIGILANT X4 CRT-D Normalized: vigilant x4 crt d |
Device | Boston Scientific Corporation | $26.87 | 2 | 2025 |
Source payment records
|
|||||
| ENSOETM Normalized: ensoetm |
Device | CARDIVA MEDICAL, INC. | $24.93 | 2 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| ACUITY Steerable Normalized: acuity steerable |
Device | Boston Scientific Corporation | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| RELIANCE 4-FRONT Normalized: reliance 4 front |
Device | Boston Scientific Corporation | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| CROME DR MRI SURESCAN Normalized: crome dr mri surescan |
Device | Medtronic, Inc. | $9.06 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $8.83 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $7.74 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $6.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 475 | 147 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 137 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 108 |
| Sotalol | Sotalol Hcl | 112 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 110 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 96 | 43 |
| Minocycline Hcl | Minocycline Hcl | 88 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 32 |
| Furosemide | Furosemide | 70 | 28 |
| Carvedilol | Carvedilol | 65 | 24 |
| Xarelto | Rivaroxaban | 53 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 34 |
| Losartan Potassium | Losartan Potassium | 41 | 17 |
| Flecainide Acetate | Flecainide Acetate | 37 | 13 |
| Spironolactone | Spironolactone | 31 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | 15 |
| Lisinopril | Lisinopril | 27 | 11 |
| Valsartan | Valsartan | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,685.63 · 161 records | Impulse Dynamics (USA) Inc. | ACUITY Steerable, ASSURITY, ATRICLIP LAA EXCLUSION SYSTEM, AVEIR, AZURE XT DR MRI SURESCAN, Assure WCD, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, CROME DR MRI SURESCAN, ENSITE PRECISION, ENSOETM, GALLANT, General - Brady, INGEVITY+, JOT DX, LifeVest, MICRA, MYNX CONTROL, MYNX CONTROL VENOUS, NUVISION ICE CATHETER, OCTARAY MAPPING CATHETER, Optimizer, QDOT MICRO, RELIANCE 4-FRONT, REVEAL LINQ, TEG5000 HEMOSTASIS ANALYZER, TEG6S HEMOSTASIS SYSTEM, VIEWMATE, VIGILANT X4 CRT-D, VersaCross Steerable Access Solution, WATCHMAN Access System, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error